Literature DB >> 22826080

Pulmonary arterial hypertension in patients with sarcoidosis: the Pulsar single center experience.

Stefan Pabst1, Christoph Hammerstingl, Natalie Grau, Jens Kreuz, Christian Grohe, Uwe R Juergens, Georg Nickenig, Dirk Skowasch.   

Abstract

Sarcoidosis is a systemic granulomatous disease with unknown etiology. Lungs and lymph nodes are commonly affected. Also, cases of pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) are described. However, the exact prevalence of PAH in patients with sarcoidosis is unclear. A 111 patients with proven sarcoidosis were recruited from January 2010 to October 2010. All patients were studied prospectively by transthoracic echocardiography (TTE) for the presence of PH. In assumed PH, a right heart catheterization (RHC) followed if there were no other reasons for PH. In 23 of the 111 patients (21%) PH was assumed in TTE. Three patients presented with severe mitral insufficiency III° and IV°, in eight patients PH was supposed to be caused by chronic heart failure or relevant diastolic dysfunction > II°, two patients declined undergoing RHC. Of the ten patients investigated with RHC, four showed a precapillary pulmonary arterial hypertension and in one patient a postcapillary hypertension was diagnosed. All four patients with precapillary PH had a radiologic stage III and IV. In three of the four patients a significantly reduced transfer factor for carbon monoxide (TLCO) <50% was found. All patients with precapillary PH had a chronic course of sarcoidosis lasting ≥13 years. This is the first study which prospectively investigated a large cohort of patients with sarcoidosis for the prevalence of PH and PAH. The prevalence of precapillary PH was found to be at least 3.6% (4/111) and therefore exceeds the prevalence of PAH in the normal population by far. A chronic and progressive lung involvement due to sarcoidosis seems to be the most evident risk factor for developing a sarcoidosis PH.

Entities:  

Mesh:

Year:  2013        PMID: 22826080     DOI: 10.1007/978-94-007-4546-9_38

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension.

Authors:  Allan Lawrie; Neil Hamilton; Steven Wood; Fernando Exposto; Ruvimbo Muzwidzwa; Louise Raiteri; Amélie Beaudet; Audrey Muller; Rafael Sauter; Nadia Pillai; David G Kiely
Journal:  Pulm Circ       Date:  2022-09-30       Impact factor: 2.886

2.  Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline.

Authors:  Elliott D Crouser; Lisa A Maier; Kevin C Wilson; Catherine A Bonham; Adam S Morgenthau; Karen C Patterson; Eric Abston; Richard C Bernstein; Ron Blankstein; Edward S Chen; Daniel A Culver; Wonder Drake; Marjolein Drent; Alicia K Gerke; Michael Ghobrial; Praveen Govender; Nabeel Hamzeh; W Ennis James; Marc A Judson; Liz Kellermeyer; Shandra Knight; Laura L Koth; Venerino Poletti; Subha V Raman; Melissa H Tukey; Gloria E Westney; Robert P Baughman
Journal:  Am J Respir Crit Care Med       Date:  2020-04-15       Impact factor: 21.405

3.  Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Shijie Zhang; Xiang Tong; Tianli Zhang; Dongguang Wang; Sitong Liu; Lian Wang; Hong Fan
Journal:  Front Cardiovasc Med       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.